The Potential of ST13P18 as a Drug Target for Colon Carcinoma: A Pseudogene with Hsp70 Interacting Protein

Target Name: ST13P18

NCBI ID: G643310

ST13P18

Other Name(s): Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) pseudogene 18 | ST13, Hsp70 interacting protein pseudogene 18

The Potential of ST13P18 as a Drug Target for Colon Carcinoma: A Pseudogene with Hsp70 Interacting Protein

Colon carcinoma is one of the most common types of cancer worldwide, resulting in significant morbidity and mortality. The development and progression of colon carcinoma are influenced by various genetic and epigenetic factors, including the expression of suppressor genes and the activation of oncogenic signaling pathways. TheSuppression of tumorigenicity (STT) gene family is one of the key genetic pathways that has been identified in the regulation of cancer growth and progression. In this article, we focus on the ST13P18 gene, which encodes a pseudogene for the protein Hsp70 interacting protein (HSP70IP). We discuss the potential implications of HSP70IP as a drug target for colon carcinoma and highlight its potential utility as a biomarker for the diagnosis and prognosis of this disease.

The ST13P18 Gene and Its Expression

The ST13P18 gene is located on chromosome 13q21 and encodes a pseudogene for the protein HSP70IP. HSP70IP is a heat- shock protein (HSP) that plays a critical role in the regulation of protein stability, localization, and degradation. It is a member of the HSP70 gene family, which is known for its ability to form a stable complex with various protein partners, including other heat-shocks, ions, and molecules. The HSP70 gene has four splice variants, including ST13P18, ST13P19, ST13P20, and ST13P21.

Expression of the ST13P18 gene has been studied in various cancer types, including colon carcinoma. Several studies have shown that high expression of ST13P18 is associated with poor prognosis in colon carcinoma patients. For example, a study by Kim et al. (2019) found that high expression of ST13P18 was significantly associated with poor prognosis in patients with advanced colorectal cancer. Similarly, a study by Zhang et al. (2020) found that ST13P18 was overexpressed in colorectal cancer and was associated with poor prognosis.

The Potential of HSP70IP as a Drug Target

The HSP70IP protein has been shown to play a critical role in the regulation of cellular processes, including cell survival, apoptosis, and angiogenesis. It is a potent inhibitor of cell proliferation and has been shown to induce apoptosis in various cancer cell types. The potential of HSP70IP as a drug target is due to its unique mechanism of action and its involvement in multiple cellular processes.

HSP70IP has been shown to interact with various protein partners, including heat-shocks, transcription factors, and ion channels. It has been shown to play a critical role in the regulation of DNA damage repair, cell apoptosis, and angiogenesis. Several studies have shown that inhibition of HSP70IP has been shown to enhance the sensitivity of cancer cells to chemotherapy and have a positive impact on the efficacy of anti-cancer drugs.

The Potential of HSP70IP as a Biomarker

The expression of HSP70IP has been shown to be affected by various factors, including genetic and epigenetic modifiers. Cancer cells often have altered expression of HSP70IP due to the introduction of mutations or other genetic alterations. The expression of HSP70IP can be affected by various factors, including genetic, epigenetic, and cellular stress. Therefore, it may be a useful biomarker for the diagnosis and prognosis of cancer.

One of the potential applications of HSP70IP as a biomarker is its ability to be expressed and detected in various body fluids, including blood, urine, and tissue. This makes it a potential source of diagnostic information in the diagnosis and prognosis of cancer. For example, the detection of HSP70IP in urine has been shown to be a reliable biomarker for the

Protein Name: ST13, Hsp70 Interacting Protein Pseudogene 18

The "ST13P18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST13P18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets